Evidence map›Paper›PMID 42564339›Full record

ArticleFrontiers in aging neuroscience2026

The Vall d'Hebron Initiative for Parkinson (VHIP) cohort: a prospective, longitudinal, and observational study enrolling

Daniela Samaniego, Silvia Enríquez-Calzada, Laura Domingo, Mar Armengol, Maria Camprodón, Laura Melgarejo, Mercedes Arrúe-Gonzalo, Maria Miret-Milian, Victoria González, Sara Belmonte and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Daniela SamaniegoNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Silvia Enríquez-CalzadaNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Laura DomingoNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Mar ArmengolNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Maria CamprodónNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Laura MelgarejoNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Mercedes Arrúe-GonzaloNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Maria Miret-MilianNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Victoria GonzálezNeurology Unit, University Hospital Vall d'Hebron, Barcelona, Spain.
Sara BelmonteNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Sara Lucas-Del-PozoNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Helena XicoyNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Anna López CarrascoNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Jordi RieraNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Eddie PradasNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Pablo Castillo-SánchezNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Marta MontpeyóNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
David MontpeyóNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Miguel A ZapataOphthalmology Unit, University Hospital Vall d'Hebron, Barcelona, Spain.
Miquel VilaNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Marta Martínez-VicenteNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Ariadna LagunaNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Jorge Hernández-VaraNeurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Instituto de Investigación Sanitaria Acreditado Hospital Universitario Vall d'Hebron (IIS IR-HUVH), Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder causing a variety of motor and non-motor symptoms. To date, no disease modifying treatment exists, and diagnosis is based on the manifestation of the clinical motor symptoms, which occurs when the neurodegenerative process is already advanced. Studies designed to find diagnostic/prognostic biomarkers and pathophysiological pathways involved in disease onset/progression are needed. Objective: To describe the study protocol of the Vall d'Hebron Initiative for Parkinson (VHIP) Cohort, a prospective and longitudinal observational cohort study aimed at deeply phenotyping Methods/Design: Subjects are prospectively recruited by movement disorder specialists at the Vall d'Hebron University Hospital (VHUH). To date, the study cohort includes 174 subjects-consisting of 117 patients with Results/Discussion: VHIP is the first study to establish a Spanish cohort combining clinical, imaging, biochemical and molecular data over time in Clinical trial registration: https://vhir.vallhebron.com/es/investigacion/proyecto-vall-dhebron-iniciativa-para-el-parkinson-vhip.

Indexed as

autonomic functionbiomarkerscohort studiesneuroimagingParkinson’s diseasevisual function

Identifiers

PMID42564339
PMCPMC13442630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.